Plain-English translation of NCT07519772 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether a new medication called can help treat two types of non-Hodgkin lymphoma: follicular lymphoma (a slower-growing cancer) and diffuse large B-cell lymphoma (a faster-growing cancer). is an immunotherapy, which means it works by training your immune system to recognize and fight the cancer cells. Researchers want to find out if the medication is safe, how well people tolerate it, and whether it can make the cancer smaller or disappear.
People with non-Hodgkin lymphoma whose cancer comes back or doesn't respond to standard treatments have limited options. This medication is being studied because it uses a different approach—boosting your own immune system—which may help patients whose cancer has proven resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the medication either as an intravenous infusion (through a vein) or as a subcutaneous injection (under the skin) depending on which study group you're assigned to. Treatment will continue for approximately 1 year or until the cancer responds, your side effects become too bothersome, or you and your doctor decide to stop. You will have regular clinic visits for monitoring, imaging scans to check if the cancer is shrinking, and blood tests to ensure your safety.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States
Argentina
China